Modified Virus and Immunotherapy for T-Cell Lymphoma
Trial Summary
What is the purpose of this trial?
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, you must not have had chemotherapy within 2 weeks or immunotherapy within 4 weeks before joining. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment for T-Cell Lymphoma?
Research shows that interleukin-12 (a protein that helps boost the immune system) therapy can lead to a significant response in cutaneous T-cell lymphoma, with about 50% of patients experiencing lesion regression. Additionally, interferon beta, when applied to skin lesions, has shown effectiveness in treating malignant lymphoma, suggesting potential benefits for similar treatments.12345
Is cemiplimab generally safe for humans?
What makes the treatment for T-Cell Lymphoma using Cemiplimab, Ipilimumab, and a modified virus unique?
This treatment is unique because it combines immunotherapy drugs (Cemiplimab and Ipilimumab) with a modified virus (Recombinant Vesicular Stomatitis Virus) that is designed to boost the immune system's ability to fight cancer cells, offering a novel approach compared to traditional therapies.2341112
Eligibility Criteria
This trial is for patients with various types of T-cell lymphoma, including peripheral T-cell lymphoma and skin lymphomas. Participants should not have a fungal infection or mouth sores. The full eligibility criteria are not provided, but typically include factors like age, health status, and prior treatments.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VSV-IFNβ-NIS, ipilimumab, and cemiplimab intravenously, with imaging and biopsies conducted throughout the study
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
Treatment Details
Interventions
- Cemiplimab (Monoclonal Antibodies)
- Ipilimumab (Checkpoint Inhibitor)
- Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter (Virus Therapy)
Cemiplimab is already approved in European Union, United States, Canada, Brazil for the following indications:
- Cutaneous squamous cell carcinoma (CSCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)
- Basal cell carcinoma (BCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)